# Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

> **NCT02281266** · PHASE4 · UNKNOWN · sponsor: **Jia Fan** · enrollment: 360 (estimated)

## Conditions studied

- Curable Hepatitis B Virus-Related Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** curative resection
- **DRUG:** thymalfasin
- **DRUG:** nucleoside analog (suggest to use entecavir)

## Key facts

- **NCT ID:** NCT02281266
- **Lead sponsor:** Jia Fan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2018-06
- **Final completion:** 2018-10
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2014-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02281266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02281266, "Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02281266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*